Home > Pressrelease > Interventional Cardiology & Peripheral Vascular Devices Market size to exceed $47Bn by 2032

Interventional Cardiology & Peripheral Vascular Devices Market size to exceed $47Bn by 2032

  • Published Date: March 31, 2023

Interventional cardiology & peripheral vascular devices market size is set to surpass USD 47 billion by 2032, as per a new research report announced by Global Market Insights Inc.

The growing incidence of cardiovascular diseases will proliferate the development of peripheral vascular and cardiology equipment. In the United States, CVD, especially ischemic heart disease, is a leading cause of mortality. This disease burden will encourage government authorities to conduct R&D on novel treatment devices. The high prevalence of hypertension has also become one of the risk factors for CVDs. These factors, along with the rising product approvals, will augment the sales of interventional cardiology devices worldwide.

Increasing occurrence of heart attacks will stimulate peripheral vascular atherectomy device manufacturing

Interventional cardiology & peripheral vascular devices market share from the atherectomy devices product segment is expected to  register 7.5% CAGR  by 2032, driven by the high cases of heart diseases. Coronary heart disease is the most common, with heart attacks claiming the lives of millions of people in the U.S. These factors will fuel the adoption of peripheral vascular atherectomy devices since they can help treat attacks through plaque removal from the artery. Likewise, the introduction of laser and rotational atherectomy and other advanced technologies will boost product adoption over the estimated timeline.

Browse key industry insights spread across 183 pages with 355 market data tables & 17 figures & charts from the report, Interventional Cardiology & Peripheral Vascular Devices Market Size By Product (Interventional Catheters, Guidewires, Stents {Bioabsorbable Stents, Drug Eluting Stents, Bare Metal Stents}, PTCA Balloons, Atherectomy Devices, Chronic Total Occlusion Devices, Synthetic Surgical Grafts, Embolic Protection Devices, Inferior Eva Cava Filters), By Application (Congenital Heart Defect Correction, Coronary Thrombectomy, Angioplasty, Valvuloplasty, Percutaneous Valve Repair), By End-use (Hospitals, Ambulatory Surgical Centers), Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2023 – 2032” in detail along with the table of contents:

Awareness of minimally invasive surgeries drives use of cardiology & peripheral vascular system in valvuloplasty

Interventional cardiology & peripheral vascular devices market revenue from the valvuloplasty segment accounted over USD 1.5 billion in 2022. The rising awareness about the benefits of minimally invasive surgical procedures over open surgeries is one of the main growth drivers. Cardiology and peripheral vascular interventional procedures are gaining momentum as therapeutic options for patients with severe aortic stenosis. High suitability of minimally invasive procedures in heart treatments such as the opening of a stiff heart valve will thus fuel product usage in valvuloplasty procedures.

Rise in geriatric population & obesity burden to boost cardiology & peripheral vascular equipment demand in Europe

Europe interventional cardiology & peripheral vascular devices market is projected to hit USD 10 billion by 2032, due to an increase in the elderly population prone to chronic diseases. Obesity and excess weight are the leading causes of death in the European region. These factors will also escalate product consumption since high body weight can increase the risk of heart failure. Moreover, the growing disposable income and the preference for innovative healthcare devices will add impetus to regional industry expansion over the forecast period.

Strategic collaborations by major players to define industry landscape

Some of the major manufacturers of interventional cardiology and peripheral vascular devices include Medtronic plc, B. Braun Melsungen AG, C.R. Bard (BD), Biotronik SE & Co. KG, Cardinal Health, Teleflex Inc., W. L. Gore & Associates Inc., Cook Medical, Boston Scientific Corporation, AngioDynamics, and Abbott Laboratories, among others.

Authors: Rupali Swain, Subodh Kharad